JP7611908B2 - 抗血球凝集素抗体およびその使用方法 - Google Patents

抗血球凝集素抗体およびその使用方法 Download PDF

Info

Publication number
JP7611908B2
JP7611908B2 JP2022523575A JP2022523575A JP7611908B2 JP 7611908 B2 JP7611908 B2 JP 7611908B2 JP 2022523575 A JP2022523575 A JP 2022523575A JP 2022523575 A JP2022523575 A JP 2022523575A JP 7611908 B2 JP7611908 B2 JP 7611908B2
Authority
JP
Japan
Prior art keywords
antibody
influenza
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553703A5 (cg-RX-API-DMAC7.html
JP2022553703A (ja
Inventor
アリーナ バウム
クリストス カイラツォウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022553703A publication Critical patent/JP2022553703A/ja
Publication of JP2022553703A5 publication Critical patent/JP2022553703A5/ja
Application granted granted Critical
Publication of JP7611908B2 publication Critical patent/JP7611908B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
JP2022523575A 2019-10-28 2020-10-28 抗血球凝集素抗体およびその使用方法 Active JP7611908B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US62/926,914 2019-10-28
US202063094170P 2020-10-20 2020-10-20
US63/094,170 2020-10-20
PCT/US2020/057635 WO2021086899A1 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022553703A JP2022553703A (ja) 2022-12-26
JP2022553703A5 JP2022553703A5 (cg-RX-API-DMAC7.html) 2023-09-26
JP7611908B2 true JP7611908B2 (ja) 2025-01-10

Family

ID=73498317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523575A Active JP7611908B2 (ja) 2019-10-28 2020-10-28 抗血球凝集素抗体およびその使用方法

Country Status (13)

Country Link
US (2) US11773156B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051707A1 (cg-RX-API-DMAC7.html)
JP (1) JP7611908B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220088446A (cg-RX-API-DMAC7.html)
CN (2) CN114761428B (cg-RX-API-DMAC7.html)
AU (2) AU2020374878B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007923A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022001067A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005281A2 (cg-RX-API-DMAC7.html)
IL (1) IL292353A (cg-RX-API-DMAC7.html)
MY (1) MY207220A (cg-RX-API-DMAC7.html)
PH (1) PH12022550963A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021086899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523805A (ja) 2014-07-15 2017-08-24 メディミューン,エルエルシー 抗b型インフルエンザ抗体の中和及びその使用
JP2018503361A (ja) 2014-12-19 2018-02-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. インフルエンザ赤血球凝集素に対するヒト抗体
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP2019521674A (ja) 2016-06-15 2019-08-08 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 B型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
HUE037659T2 (hu) * 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
AU2015214146B2 (en) * 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2016012530A (es) * 2014-03-27 2017-01-05 Genentech Inc Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
MX389708B (es) * 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
AU2016270147B2 (en) 2015-06-03 2018-08-23 Xiamen University Broad-spectrum monoclonal anti-flu B antibody and uses thereof
SG11202006379UA (en) * 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523805A (ja) 2014-07-15 2017-08-24 メディミューン,エルエルシー 抗b型インフルエンザ抗体の中和及びその使用
JP2018503361A (ja) 2014-12-19 2018-02-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. インフルエンザ赤血球凝集素に対するヒト抗体
JP2019521674A (ja) 2016-06-15 2019-08-08 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLOS Pathogens,2013年,Vol.9, Issue 2, e1003150,pp.1-12
Sci. Transl. Med.,2017年,Vol.9, eaam5752,pp.1-12

Also Published As

Publication number Publication date
BR112022007923A2 (pt) 2022-07-26
CN122521584A (zh) 2026-08-07
MY207220A (en) 2025-02-06
AU2025271140A1 (en) 2026-01-22
WO2021086899A1 (en) 2021-05-06
CO2022005281A2 (es) 2022-05-10
IL292353A (en) 2022-06-01
EP4051707A1 (en) 2022-09-07
KR20220088446A (ko) 2022-06-27
CA3153944A1 (en) 2021-05-06
CN114761428B (zh) 2026-05-22
US11773156B2 (en) 2023-10-03
JP2022553703A (ja) 2022-12-26
PH12022550963A1 (en) 2023-09-25
AU2020374878B2 (en) 2025-10-16
US20210171612A1 (en) 2021-06-10
US20240083983A1 (en) 2024-03-14
CN114761428A (zh) 2022-07-15
AU2020374878A1 (en) 2022-04-28
CL2022001067A1 (es) 2023-01-27

Similar Documents

Publication Publication Date Title
US11453714B2 (en) Human antibodies to influenza hemagglutinin
JP7796918B2 (ja) エボラウイルス糖タンパク質に対するヒト抗体
CN114057869A (zh) 针对中东呼吸综合征-冠状病毒刺突蛋白的人抗体
JP7372925B2 (ja) インフルエンザヘマグルチニンに対するヒト抗体
AU2025271140A1 (en) Anti-hemagglutinin antibodies and methods of use thereof
EA046393B1 (ru) Антитела к гемагглютинину и их применение
EA044791B1 (ru) Человеческие антитела к гемагглютинину вируса гриппа

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241224

R150 Certificate of patent or registration of utility model

Ref document number: 7611908

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150